LE WE PMID CA
Colon and rectum (Neoplasia)1479Kolon und Rektum (Neubildung)

5 Aminosalicylate

5T4 Oncotrophoblast glycoprotein

Anus (Neoplasm)

ATP5A1

Bevacizumab ttVEGF

BRAF

Capecitabine

Cell stress (BASKET)

Cetuximab ttEGFR

Chemoprevention

Cholic acid

Chromoendoscopy

Colon and rectum (aberrant crypt foci)

Colon and rectum (CT)

Colon and rectum (Neoplasia)

Colon and rectum (Polyp)

CpG island

CRAC

Epithelio mesenchymal transition

ERG transcription factor

ERS UFR (Toxikologie)

Genetic instability

Genetics (Microsatellite)

Inflammatory bowel diseases

Interleukin17

Irinotecan

JC Virus

Kidney (Neoplasia RCC)

KRAS

Lynch syndrome

Mammary gland (Neoplasia)

Medical ethics

MLH1

MSH2

MSH6

MTUS1

MUTYH

MYH

Neoplasia (Carcinogenesis)

Neoplasia (Inherited)

Neoplasia (Invasion and metastasis)

Neoplasia (Tumor biology and immunology)

Neoplasia (Tumor markers)

Neuroendocrine System (Neoplasia Carcinoid)

Notch

Optical imaging (Instrumentation)

Oxaliplatin

Panitumomab ttEGFR

PI3KC3

PMS2

Prostate (Neoplasia)

Raltitrexed

Receptor (PPAR gamma)

RNA (MicroRNA)

S100A4

SEPT9

TGF beta

Tivozanib ttVEGF

UFT

UGT1A1

Ursodeoxycholic acid

Vaccine (Oncology)

Wnt beta Catenin TCF

1988  
1
Dukes' classification of rectal cancer.
[3279538] South Med J 81(3): 407-8 (1988)
2003  
2
2005  
3
Hereditary non-polyposis colon cancer.
[16025587] Ulster Med J 74(1): 14-21 (2005)
1992  
4
Familial adenomatous polyposis.
[1311383] J R Soc Med 85(2): 63-5 (1992)
2010  
5
The differential diagnosis and surveillance of hereditary gastrointestinal polyposis syndromes.
[20358032] Dtsch Arztebl Int 107(10): 163-73 (2010)
2009  
6
Colorectal carcinoma: the management of polyps, (neo)adjuvant therapy, and the treatment of metastases.
[20062582] Dtsch Arztebl Int 106(51-52): 843-8 (2009)
2007  
7
A review of the role of capecitabine in the treatment of colorectal cancer.
[18488072] Ther Clin Risk Manag 3(3): 421-31 (2007)
2008  
8
The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
[18462574] Health Technol Assess 12(15): iii-ix, xi-162 (2008)
2007  
9
Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
[17346499] Health Technol Assess 11(12): 1-128, iii-iv (2007)
2006  
10
Clinical effectiveness and cost-effectiveness of laparoscopic surgery for colorectal cancer: systematic reviews and economic evaluation.
[17083853] Health Technol Assess 10(45): 1-141, iii-iv (2006)
2006  
11
The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
[17049138] Health Technol Assess 10(41): iii-iv, xi-xiv, 1-185 (2006)
2010  
12
Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer.
[21042543] Core Evid 5(-): 61-76 (2010)
2008  
13
Extracolonic manifestations of hereditary colorectal cancer syndromes.
[20011437] Clin Colon Rectal Surg 21(4): 263-72 (2008)
2009  
14
Early detection of and screening for colorectal neoplasia.
[20431727] Gut Liver 3(2): 69-80 (2009)
2008  
15
Noninvasive molecular biomarkers for the detection of colorectal cancer.
[18959813] BMB Rep 41(10): 685-92 (2008)
2006  
16
Induction chemoradiation for rectal cancer.
[17178968] Arch Surg 141(12): 1246-52; discussion 1253 (2006)
1999  
17
1995  
18
Colorectal cancer: surgical prophylaxis and chemoprevention.
[7486766] Ann R Coll Surg Engl 77(5): 372-6 (1995)
1995  
19
Adjuvant chemotherapy for colorectal cancer.
[7793820] Ann R Coll Surg Engl 77(2): 81-4 (1995)
2004  
20
Anterior resection for rectal cancer with mesorectal excision: a prospective evaluation of 622 patients.
[15273550] Ann Surg 240(2): 260-8 (2004)
2002  
21
Long-term results of local excision for rectal cancer.
[12368681] Ann Surg 236(4): 522-29; discussion 529-30 (2002)
2001  
22
Neoadjuvant chemoradiation for rectal cancer: analysis of clinical outcomes from a 13-year institutional experience.
[11371736] Ann Surg 233(6): 778-85 (2001)
2001  
23
Comparison of quality of life in patients undergoing abdominoperineal extirpation or anterior resection for rectal cancer.
[11176119] Ann Surg 233(2): 157-8 (2001)
1998  
24
Periampullary adenocarcinoma: analysis of 5-year survivors.
[9637545] Ann Surg 227(6): 821-31 (1998)
1998  
25
Surgical treatment of adenocarcinoma of the rectum.
[9637543] Ann Surg 227(6): 800-11 (1998)
1995  
26
Clinical behavior and prognostic factors of periampullary adenocarcinoma.
[7487210] Ann Surg 222(5): 632-7 (1995)
1989  
27
Sphincter-saving procedures for distal carcinoma of the rectum.
[2642688] Ann Surg 209(1): 1-18 (1989)
1988  
28
Is total pelvic exenteration reasonable primary treatment for rectal carcinoma?
[3291792] Ann Surg 207(6): 670-8 (1988)
1966  
29
Carcinoma of the distal large bowel: 32-year review of 1,026 cases.
[5933798] Ann Surg 163(6): 838-49 (1966)
1966  
30
Cancer of the colon, rectum and anus: review of 1,687 cases.
[5933797] Ann Surg 163(6): 829-37 (1966)
2004  
31
The evolution to stool DNA testing for colorectal cancer.
[15191503] Aliment Pharmacol Ther 19(12): 1225-33 (2004)
2003  
32
Review article: colorectal cancer chemotherapy.
[14510741] Aliment Pharmacol Ther 18(7): 683-92 (2003)
2002  
33
Review article: genetic testing and counselling for hereditary colorectal cancer.
[12390093] Aliment Pharmacol Ther 16(11): 1843-57 (2002)
2001  
34
Review article: non-systemic chemotherapy in the treatment of colorectal cancer-portal vein, hepatic arterial and intraperitoneal approaches.
[11563991] Aliment Pharmacol Ther 15(10): 1527-41 (2001)
2008  
35
Review article: panitumumab--a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer.
[19086328] Aliment Pharmacol Ther 28(3): 269-81 (2008)
2008  
36
Review article: current management of metastatic colorectal cancer - the evolving impact of targeted drug therapies.
[18363897] Aliment Pharmacol Ther 27(11): 997-1005 (2008)
2007  
37
Predictive and prognostic markers in colorectal cancer.
[19262902] Gastrointest Cancer Res 1(6): 237-46 (2007)
2010  
38
Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.
[20383783] Target Oncol 5(1): 19-28 (2010)
2009  
39
Implications of KRAS mutation status for the treatment of metastatic colorectal cancer.
[19915942] Target Oncol 4(4): 311-22 (2009)
2009  
40
Microsatellite instability: a predictive marker in metastatic colorectal cancer?
[19343302] Target Oncol 4(1): 57-62 (2009)
2008  
41
UFT (tegafur-uracil) in rectal cancer.
[18381370] Ann Oncol 19(8): 1371-8 (2008)
2008  
42
Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
[18456760] Ann Oncol 19 Suppl 2(-): ii33-4 (2008)
2008  
43
Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
[18456759] Ann Oncol 19 Suppl 2(-): ii31-2 (2008)
2008  
44
Colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up.
[18456758] Ann Oncol 19 Suppl 2(-): ii29-30 (2008)
2007  
45
Integrative decisions in rectal cancer.
[17631565] Ann Oncol 18 Suppl 9(-): ix127-31 (2007)
2007  
46
The multidisciplinary treatment of rectal cancer: pathology.
[17631564] Ann Oncol 18 Suppl 9(-): ix122-6 (2007)
2007  
47
Multidisciplinary treatment of rectal cancer: medical oncology.
[17631563] Ann Oncol 18 Suppl 9(-): ix114-21 (2007)
2007  
48
Radiotherapy for localized rectal cancer.
[17631562] Ann Oncol 18 Suppl 9(-): ix105-13 (2007)
2007  
49
Cetuximab: clinical results in colorectal cancer.
[17591840] Ann Oncol 18 Suppl 6(-): vi8-10 (2007)
2006  
50
A multimodality approach to localized rectal cancer.
[17018713] Ann Oncol 17 Suppl 10(-): x129-34 (2006)
2006  
51
The integration of targeted agents into systemic therapy of metastatic colorectal cancer.
[17018712] Ann Oncol 17 Suppl 10(-): x122-8 (2006)
2006  
52
Adjuvant therapy in colon cancer--what, when and how?
[16524974] Ann Oncol 17(9): 1347-59 (2006)
2006  
53
Alternative clinical end points in rectal cancer--are we getting closer?
[16873440] Ann Oncol 17(8): 1239-48 (2006)
2005  
54
Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates.
[15870084] Ann Oncol 16(8): 1311-9 (2005)
2005  
55
(Neo-)adjuvant treatments in colorectal cancer.
[15958444] Ann Oncol 16 Suppl 2(-): ii133-40 (2005)
2004  
56
Importance of microsatellite instability (MSI) in colorectal cancer: MSI as a diagnostic tool.
[15477322] Ann Oncol 15 Suppl 4(-): iv283-4 (2004)
2002  
57
Molecular and biochemical markers in colorectal cancer.
[12401696] Ann Oncol 13 Suppl 4(-): 235-45 (2002)
2001  
58
Microsatellite instability: application in hereditary non-polyposis colorectal cancer.
[11300317] Ann Oncol 12(2): 151-60 (2001)
2007  
59
Adjuvant treatment of colorectal cancer.
[17507442] CA Cancer J Clin 57(3): 168-85 (2007)
1997  
60
Surgical treatment of colorectal cancer.
[9074489] CA Cancer J Clin 47(2): 113-28 (1997)
1997  
61
Diagnosing colorectal carcinoma: clinical and molecular approaches.
[9074487] CA Cancer J Clin 47(2): 70-92 (1997)
2008  
62
Systemic therapy for metastatic colorectal cancer: current questions.
[18338815] Cancer 112(9): 1879-91 (2008)
2008  
63
Prognostic significance of mesenteric tumor nodules in patients with stage III colorectal cancer.
[18008365] Cancer 112(1): 50-4 (2008)
2007  
64
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.
[17671985] Cancer 110(5): 980-8 (2007)
2005  
65
Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma.
[15880563] Cancer 103(12): 2435-46 (2005)
2004  
66
Adjuvant postoperative radiotherapy for colon carcinoma.
[15316945] Cancer 101(6): 1338-44 (2004)
2004  
67
New systemic frontline treatment for metastatic colorectal carcinoma.
[15073842] Cancer 100(8): 1558-77 (2004)
2010  
68
Radiation therapy for rectal cancer: current status and future directions.
[20010516] Cancer Control 17(1): 25-34 (2010)
2010  
69
An update on laparoscopic resection for rectal cancer.
[20010515] Cancer Control 17(1): 16-24 (2010)
2010  
70
Current progress in targeted therapy for colorectal cancer.
[20010514] Cancer Control 17(1): 7-15 (2010)
2003  
71
Methods and results of sphincter-preserving surgery for rectal cancer.
[12794619] Cancer Control 10(3): 212-8 (2003)
2003  
72
The role of total mesorectal excision in the management of rectal cancer.
[12794618] Cancer Control 10(3): 205-11 (2003)
2008  
73
U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
[18316547] Clin Cancer Res 14(5): 1296-302 (2008)
2007  
74
Radiation therapy in stage II and III rectal cancer.
[18006798] Clin Cancer Res 13(22 Pt 2): 6903s-8s (2007)
2007  
75
Multidisciplinary management of patients with advanced rectal cancer.
[18006795] Clin Cancer Res 13(22 Pt 2): 6890s-3s (2007)
2007  
76
Management of early rectal T1 and T2 cancers.
[18006794] Clin Cancer Res 13(22 Pt 2): 6885s-9s (2007)
2007  
77
Optimal methods for staging rectal cancer.
[18006793] Clin Cancer Res 13(22 Pt 2): 6877s-84s (2007)
2007  
78
Newer pathologic assessment techniques for colorectal carcinoma.
[18006792] Clin Cancer Res 13(22 Pt 2): 6871s-6s (2007)
2007  
79
Optimal pathologic staging: defining stage II disease.
[18006791] Clin Cancer Res 13(22 Pt 2): 6862s-70s (2007)
2009  
80
FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer.
[19282350] Oncologist 14(3): 284-90 (2009)
2007  
81
Locally advanced rectal cancer: what is the evidence for induction chemoradiation?
[18055850] Oncologist 12(11): 1309-18 (2007)
2006  
82
Novel therapeutic developments other than EGFR and VEGF inhibition in colorectal cancer.
[17030644] Oncologist 11(9): 1018-24 (2006)
2005  
83
Critical evaluation of current treatments in metastatic colorectal cancer.
[15821245] Oncologist 10(4): 250-61 (2005)
2006  
84
EphB/EphrinB receptors and Wnt signaling in colorectal cancer.
[16397205] Cancer Res 66(1): 2-5 (2006)
2006  
85
Serrated pathway and APC (conventional)-type colorectal polyps: molecular-morphologic correlations, genetic pathways, and implications for classification.
[16483003] Am J Clin Pathol 125(1): 146-53 (2006)
2005  
86
Serrated polyps of the large intestine: a morphologic and molecular review of an evolving concept.
[16191506] Am J Clin Pathol 124(3): 380-91 (2005)
2003  
87
Hyperplastic-like colon polyps that preceded microsatellite-unstable adenocarcinomas.
[12817424] Am J Clin Pathol 119(6): 778-96 (2003)
2003  
88
Hyperplastic-like polyps as precursors of microsatellite-unstable colorectal cancer.
[12817423] Am J Clin Pathol 119(6): 773-5 (2003)
2002  
89
Beta-catenin--a linchpin in colorectal carcinogenesis?
[11839557] Am J Pathol 160(2): 389-401 (2002)
1994  
90
Colon cancer connections. Cancer syndrome meets molecular biology meets histopathology.
[8030741] Am J Pathol 145(1): 1-6 (1994)
2008  
91
Guidelines for surveillance intervals after polypectomy: coping with the evidence.
[18347353] Ann Intern Med 148(6): 477-9 (2008)
2008  
92
Postpolypectomy colonoscopy surveillance guidelines: predictive accuracy for advanced adenoma at 4 years.
[18347350] Ann Intern Med 148(6): 419-26 (2008)
2003  
93
The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications.
[12667026] Ann Intern Med 138(7): 560-70 (2003)
2001  
94
Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer.
[11601929] Ann Intern Med 135(8 Pt 1): 577-88 (2001)
2001  
95
Bethesda guidelines: relation to microsatellite instability and MLH1 promoter methylation in patients with colorectal cancer.
[11601928] Ann Intern Med 135(8 Pt 1): 566-76 (2001)
1995  
96
Prevention of colorectal cancer by endoscopic polypectomy.
[7486491] Ann Intern Med 123(12): 949-50 (1995)
1993  
97
Polyp guideline: diagnosis, treatment, and surveillance for patients with nonfamilial colorectal polyps. The Practice Parameters Committee of the American College of Gastroenterology.
[8379605] Ann Intern Med 119(8): 836-43 (1993)
1963  
98
COLON AND RECTAL POLYPS. RELATIONSHIP TO CARCINOMA.
[14084684] Calif Med 99(-): 378-81 (1963)
2005  
99
Chemoradiotherapy for colorectal cancer.
[16009693] Gut 54(8): 1194-202 (2005)
2005  
100
Adherence to BSG adenoma surveillance guidelines will reduce colonoscopic workload.
[15591532] Gut 54(1): 173 (2005)
2004  
101
An update on the genetics of colorectal cancer.
[15358723] Hum Mol Genet 13 Spec No 2(-): R177-85 (2004)
2001  
102
Deficient DNA mismatch repair: a common etiologic factor for colon cancer.
[11257106] Hum Mol Genet 10(7): 735-40 (2001)
2004  
103
My approach to serrated polyps of the colorectum.
[15220357] J Clin Pathol 57(7): 682-6 (2004)
2008  
104
Molecular classification and correlates in colorectal cancer.
[18165277] J Mol Diagn 10(1): 13-27 (2008)
2005  
105
Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer.
[15855432] JAMA 293(16): 1986-94 (2005)
2003  
106
Colorectal carcinoma: diagnostic, prognostic, and molecular features.
[12692203] Mod Pathol 16(4): 376-88 (2003)
2003  
107
Gastrointestinal inherited polyposis syndromes.
[12692201] Mod Pathol 16(4): 359-65 (2003)
1983  
108
Familial colonic cancer syndromes.
[6356610] West J Med 139(3): 351-9 (1983)
2009  
109
Efficacy of the revised Vienna Classification for diagnosing colorectal epithelial neoplasias.
[19452577] World J Gastroenterol 15(19): 2351-6 (2009)
2006  
110
Complementary analysis of microsatellite tumor profile and mismatch repair defects in colorectal carcinomas.
[17009390] World J Gastroenterol 12(37): 5932-40 (2006)
2003  
111
Aberrant crypt foci as microscopic precursors of colorectal cancer.
[14669304] World J Gastroenterol 9(12): 2642-9 (2003)
2008  
112
Surgical treatment for rectal cancer: an international perspective on what the medical gastroenterologist needs to know.
[18528924] World J Gastroenterol 14(21): 3281-9 (2008)
2007  
113
Rectal cancer treatment: improving the picture.
[17990346] World J Gastroenterol 13(44): 5805-12 (2007)
2006  
114
Modern management of rectal cancer: a 2006 update.
[16718838] World J Gastroenterol 12(20): 3186-95 (2006)
2007  
115
The genetics of hereditary colon cancer.
[17938238] Genes Dev 21(20): 2525-38 (2007)
2007  
116
Flat colorectal neoplasms: definition, importance, and visualization on CT colonography.
[17377029] AJR Am J Roentgenol 188(4): 953-9 (2007)
1993  
117
Colonic submucosal tumors: a new classification based on radiologic characteristics.
[8424341] AJR Am J Roentgenol 160(2): 315-20 (1993)
1991  
118
Colorectal cancer: cross-sectional imaging for staging of primary tumor and detection of local recurrence.
[2017950] AJR Am J Roentgenol 156(5): 909-15 (1991)
2007  
119
Evaluation of submucosal lesions of the large intestine: part 1. Neoplasms.
[18025511] Radiographics 27(6): 1681-92 (2007)
2002  
120
Differential diagnosis of periampullary carcinomas at MR imaging.
[12432106] Radiographics 22(6): 1335-52 (2002)
1995  
121
From the archives of the AFIP. Colorectal adenocarcinoma: radiologic-pathologic correlation.
[7899592] Radiographics 15(1): 127-46; quiz 148-9 (1995)
2010  
122
Restaging of Rectal Cancer with MR Imaging after Concurrent Chemotherapy and Radiation Therapy.
[20228331] Radiographics 30(2): 503-16 (2010)
2004  
123
Rectal cancer: review with emphasis on MR imaging.
[15286305] Radiology 232(2): 335-46 (2004)
2000  
124
Diagnosis of colorectal neoplasms at double-contrast barium enema examination.
[10887222] Radiology 216(1): 11-8 (2000)
2011  
125
Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer.
[21779535] Am J Cancer Res 1(5): 650-62 (2011)
2010  
126
Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer--an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009.
[20219759] Ann Oncol 21(8): 1579-84 (2010)
2010  
127
Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up.
[20555107] Ann Oncol 21 Suppl 5(-): v70-7 (2010)
2010  
128
Familial colorectal cancer risk: ESMO Clinical Practice Guidelines.
[20555108] Ann Oncol 21 Suppl 5(-): v78-81 (2010)
2010  
129
Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
[20555109] Ann Oncol 21 Suppl 5(-): v82-6 (2010)
2010  
130
Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment.
[20555112] Ann Oncol 21 Suppl 5(-): v93-7 (2010)
2010  
131
What can the molecular pathologist offer for optimal decision making?
[20943604] Ann Oncol 21 Suppl 7(-): vii123-9 (2010)
2010  
132
Chemotherapy: which drug and when?
[20943605] Ann Oncol 21 Suppl 7(-): vii130-3 (2010)
2010  
133
How to integrate molecular targeted agents in the continuum of care.
[20943606] Ann Oncol 21 Suppl 7(-): vii134-9 (2010)
2005  
134
Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies.
[15923428] Ann Oncol 16 Suppl 4(-): iv44-49 (2005)
2009  
135
Primary colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up.
[19454461] Ann Oncol 20 Suppl 4(-): 49-50 (2009)
2009  
136
Familial colorectal cancer risk: ESMO clinical recommendations.
[19454462] Ann Oncol 20 Suppl 4(-): 51-3 (2009)
2009  
137
Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
[19454463] Ann Oncol 20 Suppl 4(-): 54-6 (2009)
2009  
138
Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
[19454465] Ann Oncol 20 Suppl 4(-): 61-3 (2009)
2010  
139
KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy.
[19936839] Ann Surg Oncol 17(4): 1168-76 (2010)
2008  
140
MRI for detection of extramural vascular invasion in rectal cancer.
[18941094] AJR Am J Roentgenol 191(5): 1517-22 (2008)
2009  
141
Advances in the treatment of metastatic colorectal cancer.
[19955859] Am J Ther 16(5): 412-20 (2009)
2010  
142
Prevalence and predictors of appropriate colorectal cancer surveillance in Lynch syndrome.
[20354509] Am J Gastroenterol 105(8): 1851-60 (2010)
2010  
143
MicroRNAs as biomarkers in colorectal cancer.
[20829435] Am J Pathol 177(4): 1592-9 (2010)
2011  
144
Lynch syndrome screening implementation: business analysis by a healthcare system.
[21851136] Am J Manag Care 17(8): e288-300 (2011)
2010  
145
Colorectal cancer screening: the role of CT colonography.
[20731011] World J Gastroenterol 16(32): 3987-94 (2010)
2011  
146
Multifaceted nature of membrane microdomains in colorectal cancer.
[21390137] World J Gastroenterol 17(6): 681-90 (2011)
2011  
147
Identification of patients at-risk for Lynch syndrome in a hospital-based colorectal surgery clinic.
[21390147] World J Gastroenterol 17(6): 766-73 (2011)
2011  
148
Management of stage IV rectal cancer: palliative options.
[21412493] World J Gastroenterol 17(7): 835-47 (2011)
2011  
149
Neoadjuvant vs adjuvant pelvic radiotherapy for locally advanced rectal cancer: Which is superior?
[21412494] World J Gastroenterol 17(7): 848-54 (2011)
2011  
150
Sphincter preservation for distal rectal cancer--a goal worth achieving at all costs?
[21412495] World J Gastroenterol 17(7): 855-61 (2011)
2011  
151
Isolated lymphoid follicles in colon: switch points between inflammation and colorectal cancer?
[21483625] World J Gastroenterol 17(13): 1666-73 (2011)
2011  
152
Patterns of local recurrence in rectal cancer after a multidisciplinary approach.
[21483626] World J Gastroenterol 17(13): 1674-84 (2011)
2010  
153
Surveillance for colitis-associated colon neoplasia.
[20872964] World J Gastroenterol 16(37): 4646-51 (2010)
2007  
154
Diagnostic procedures for submucosal tumors in the gastrointestinal tract.
[17659668] World J Gastroenterol 13(24): 3301-10 (2007)
2007  
155
Therapeutic procedures for submucosal tumors in the gastrointestinal tract.
[17659670] World J Gastroenterol 13(24): 3316-22 (2007)
2007  
156
Serrated neoplasia of the colorectum.
[17657832] World J Gastroenterol 13(28): 3792-8 (2007)
2007  
157
Adjuvant therapies for colorectal cancer.
[17657833] World J Gastroenterol 13(28): 3799-805 (2007)
2007  
158
Metastatic colorectal cancer-past, progress and future.
[17657834] World J Gastroenterol 13(28): 3806-15 (2007)
2007  
159
Combining chemotherapy and targeted therapies in metastatic colorectal cancer.
[17990352] World J Gastroenterol 13(44): 5867-76 (2007)
2007  
160
2011  
161
Genetics, cytogenetics, and epigenetics of colorectal cancer.
[21490705] J Biomed Biotechnol 2011(-): 792362 (2011)
2011  
162
Epithelial tight junctional changes in colorectal cancer tissues.
[21479352] ScientificWorldJournal 11(-): 826-41 (2011)
2011  
163
Molecular imaging using positron emission tomography in colorectal cancer.
[21616042] Discov Med 11(60): 435-47 (2011)
2011  
164
The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer.
[21356164] Discov Med 11(57): 95-105 (2011)
2010  
165
New strategies for treatment of KRAS mutant metastatic colorectal cancer.
[20460490] Clin Cancer Res 16(11): 2921-6 (2010)
2010  
166
A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.
[20584808] Oncologist 15(7): 699-731 (2010)
2010  
167
Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions.
[20133499] Oncologist 15(2): 157-67 (2010)
2006  
168
Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers.
[16770784] Cancer 107(2): 221-31 (2006)
2005  
169
P53 abnormalities and outcomes in colorectal cancer: a systematic review.
[15668707] Br J Cancer 92(3): 434-44 (2005)
2009  
170
Molecular origins of cancer: Molecular basis of colorectal cancer.
[20018966] N Engl J Med 361(25): 2449-60 (2009)
2003  
171
2010  
172
The origins of colorectal carcinoma: specific nomenclature for different pathways and precursor lesions.
[21085545] Dtsch Arztebl Int 107(43): 760-6 (2010)
2006  
173
How can we best detect hereditary non-polyposis colorectal cancer?
[16515428] Med J Aust 184(5): 206-7 (2006)
2010  
174
Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.
[21047491] Health Technol Assess 14(Suppl. 2): 47-53 (2010)
2010  
175
Cetuximab for the first-line treatment of metastatic colorectal cancer.
[20507797] Health Technol Assess 14 Suppl 1(-): 1-8 (2010)
2010  
176
Kras in metastatic colorectal cancer.
[21104470] Swiss Med Wkly 140(-): w13112 (2010)
2010  
177
Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis.
[21163137] Chin Med J (Engl) 123(22): 3314-8 (2010)
2006  
178
2006  
179
2006  
180
2010  
181
Ursodeoxycholic acid and chemoprevention of colorectal cancer.
[20609543] Gastroenterol Clin Biol 34(10): 516-22 (2010)
2011  
182
Fecal occult blood testing while waiting for screening colonoscopy in average-risk individuals: durable option or short-term solution?
[21647456] Can J Gastroenterol 25(5): 247 (2011)
2003  
183
Elastofibromatous polyp of the sigmoid colon--a case report and review of gastrointestinal elastofibromas.
[12704473] Can J Gastroenterol 17(4): 275-7 (2003)
2007  
184
Colorectal cancer: imaging surveillance following resection of primary tumour.
[17921088] Cancer Imaging 7 Spec No A(-): S143-9 (2007)
2011  
185
Strategies in screening for colon carcinoma.
[21444935] Neth J Med 69(3): 112-9 (2011)
2005  
186
Targeted therapies in the treatment of colorectal cancers.
[15855893] Cancer Control 12(2): 105-10 (2005)
2005  
187
Genomic instability and colorectal cancer.
[16351460] Rev Esp Enferm Dig 97(10): 683-7 (2005)
2005  
188
Hereditary nonpolyposis colorectal cancer identification and surveillance of high-risk families.
[15962087] Clinics (Sao Paulo) 60(3): 251-6 (2005)
2010  
189
Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget.
[21317460] Oncotarget 1(7): 651-61 (2010)
2007  
190
Epidemiology of colonic aberrant crypt foci: review and analysis of existing studies.
[17182176] Cancer Lett 252(2): 171-83 (2007)
2008  
191
Pro-inflammatory prostaglandins and progression of colorectal cancer.
[18406516] Cancer Lett 267(2): 197-203 (2008)
2009  
192
Should computed tomographic colonography replace optical colonoscopy in screening for colorectal cancer?
[19413183] Pol Arch Med Wewn 119(4): 236-41 (2009)
2009  
193
Role of Notch signaling in colorectal cancer.
[19793799] Carcinogenesis 30(12): 1979-86 (2009)
2008  
194
Updating the management of rectal cancer.
[18392247] J Gastrointestin Liver Dis 17(1): 69-74 (2008)
2008  
195
Hydrophobic bile acids, genomic instability, Darwinian selection, and colon carcinogenesis.
[21677822] Clin Exp Gastroenterol 1(): 19-47 (2008)
2010  
196
JC virus in the pathogenesis of colorectal cancer, an etiological agent or another component in a multistep process?
[20167111] Virol J 7(-): 42 (2010)
2008  
197
K-Ras mutation status as a predictive biomarker in metastatic colorectal cancer.
[20477429] Biomark Med 2(2): 97-9 (2008)
2010  
198
Role of transforming growth factor-β in inflammatory bowel disease and colitis-associated colon cancer.
[20848467] Inflamm Bowel Dis 16(11): 1963-8 (2010)
2007  
199
Role of chromoendoscopy in colon cancer surveillance in inflammatory bowel disease.
[17309075] Inflamm Bowel Dis 13(7): 911-7 (2007)
2009  
200
Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn's disease of the colon.
[18942763] Inflamm Bowel Dis 15(4): 630-8 (2009)
2008  
201
Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update.
[17932965] Inflamm Bowel Dis 14(2): 265-74 (2008)
2007  
202
The canonical Wnt signalling pathway and its APC partner in colon cancer development.
[16840506] Gut 56(3): 417-25 (2007)
2010  
203
Hereditary and familial colon cancer.
[20420945] Gastroenterology 138(6): 2044-58 (2010)
2010  
204
Primary prevention of colorectal cancer.
[20420944] Gastroenterology 138(6): 2029-2043.e10 (2010)
2010  
205
Optical molecular imaging approaches in colorectal cancer.
[20026448] Gastroenterology 138(2): 419-22 (2010)
2008  
206
Genomic and epigenetic instability in colorectal cancer pathogenesis.
[18773902] Gastroenterology 135(4): 1079-99 (2008)
2008  
207
Systemic treatment of colorectal cancer.
[18471507] Gastroenterology 134(5): 1296-310 (2008)
2011  
208
Canadian Expert Group consensus recommendations: KRAS testing in colorectal cancer.
[21874108] Curr Oncol 18(4): e180-4 (2011)
2009  
209
Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy.
[19386128] J Hematol Oncol 2(-): 18 (2009)
2008  
210
Nomenclature, molecular genetics and clinical significance of the precursor lesions in the serrated polyp pathway of colorectal carcinoma.
[18787610] Int J Clin Exp Pathol 1(4): 317-24 (2008)
2009  
211
How much does colonoscopy reduce colon cancer mortality?
[19075200] Ann Intern Med 150(1): 50-2 (2009)
2007  
212
Hereditary nonpolyposis colorectal cancer: diagnostic strategies and their implications.
[17764220] Evid Rep Technol Assess (Full Rep) -(150): 1-180 (2007)
2011  
213
Mouse models of colorectal cancer.
[21718591] Chin J Cancer 30(7): 450-62 (2011)
2011  
214
Capecitabine in the management of colorectal cancer.
[21629830] Cancer Manag Res 3(-): 79-89 (2011)
2011  
215
Preventing bowel cancer: an insight for clinicians.
[22084641] Ther Adv Med Oncol 3(6): 269-77 (2011)
2007  
216
Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care.
[21221177] Core Evid 2(2): 81-8 (2007)
2011  
217
CpG island methylation in colorectal cancer: past, present and future.
[21559209] Patholog Res Int 2011(-): 902674 (2011)
2011  
218
Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic therapies.
[21773077] World J Clin Oncol 2(6): 272-80 (2011)
2008  
219
2009  
220
Overview of systemic therapy for colorectal cancer.
[21037816] Clin Colon Rectal Surg 22(4): 251-6 (2009)
2009  
221
Surveillance after curative resection of colorectal cancer.
[21037815] Clin Colon Rectal Surg 22(4): 242-50 (2009)
2009  
222
Screening options and recommendations for colorectal cancer.
[21037811] Clin Colon Rectal Surg 22(4): 209-17 (2009)
2007  
223
Recently identified colon cancer predispositions: MYH and MSH6 mutations.
[17920897] Semin Oncol 34(5): 418-24 (2007)
2010  
224
Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond.
[20932136] Expert Rev Gastroenterol Hepatol 4(5): 525-9 (2010)
2011  
225
Emerging role of vitamin D in colorectal cancer.
[22007275] World J Gastrointest Oncol 3(8): 123-7 (2011)
2010  
226
Peroxisome proliferator-activated receptor γ and colorectal cancer.
[21160824] World J Gastrointest Oncol 2(3): 159-64 (2010)
2002  
227
Colorectal cancer: targeting metastasis and angiogenesis.
[12450417] Clin Colorectal Cancer 1(4): 200 (2002)
2002  
228
Matrix metalloproteinases in colorectal cancer.
[12450419] Clin Colorectal Cancer 1(4): 208-19 (2002)
2008  
229
Role of combined-modality therapy in the management of locally advanced rectal cancer.
[19036689] Clin Colorectal Cancer 7(6): 369-75 (2008)
2008  
230
Local excision for rectal carcinoma.
[19036690] Clin Colorectal Cancer 7(6): 376-85 (2008)
2009  
231
Colonic carcinoid tumors: a clinicopathologic study of 23 patients from a single institution.
[20232008] Arq Gastroenterol 46(4): 288-93 (2009)
2010  
232
Recent insights into the pathogenesis of colorectal cancer.
[19786869] Curr Opin Gastroenterol 26(1): 47-52 (2010)
2010  
233
Targeted imaging of flat and depressed colonic neoplasms.
[20656254] Gastrointest Endosc Clin N Am 20(3): 579-83 (2010)
2009  
234
Genetic testing for hereditary colorectal cancer.
[19793575] Surg Oncol Clin N Am 18(4): 687-703 (2009)
2011  
235
Clinical characteristics of colorectal carcinoid tumors.
[21431092] J Korean Soc Coloproctol 27(1): 17-20 (2011)
2011  
236
Current management of inflammatory bowel disease and colorectal cancer.
[21673876] Gastrointest Cancer Res 4(2): 53-61 (2011)
2011  
237
Wnt signaling and colon carcinogenesis: beyond APC.
[21483657] J Carcinog 10(-): 5 (2011)
2010  
238
JC virus infection: a cause of colorectal cancer?
[20520564] J Clin Gastroenterol 44(7): 466-8 (2010)
2010  
239
Current clinical criteria for Lynch syndrome are not sensitive enough to identify MSH6 mutation carriers.
[20587412] J Med Genet 47(9): 579-85 (2010)
2010  
240
Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials.
[20504361] J Exp Clin Cancer Res 29(-): 58 (2010)
2010  
241
Gene dysregulations driven by somatic copy number aberrations-biological and clinical implications in colon tumors: a paper from the 2009 William Beaumont Hospital Symposium on Molecular Pathology.
[20709793] J Mol Diagn 12(5): 552-61 (2010)
2010  
242
Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma.
[20413677] J Mol Diagn 12(4): 433-40 (2010)
2011  
243
An update on TroVax for the treatment of progressive castration-resistant prostate cancer.
[21691576] Onco Targets Ther 4(-): 33-41 (2011)
2007  
244
Blood markers for early detection of colorectal cancer: a systematic review.
[17932341] Cancer Epidemiol Biomarkers Prev 16(10): 1935-53 (2007)
2009  
245
Prospective study of JC virus seroreactivity and the development of colorectal cancers and adenomas.
[19383887] Cancer Epidemiol Biomarkers Prev 18(5): 1515-23 (2009)
2009  
246
Apoptosis in the colonic crypt, colorectal adenomata, and manipulation by chemoprevention.
[19505899] Cancer Epidemiol Biomarkers Prev 18(6): 1680-7 (2009)
2009  
247
Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives.
[19125126] Genet Med 11(1): 35-41 (2009)
2009  
248
EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome.
[19125127] Genet Med 11(1): 42-65 (2009)
2009  
249
Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review.
[19125129] Genet Med 11(1): 21-34 (2009)
2010  
250
Colorectal cancer: molecular features and clinical opportunities.
[20498827] Clin Biochem Rev 31(2): 31-8 (2010)
2009  
251
Wnt up your mind - intervention strategies for S100A4-induced metastasis in colon cancer.
[20093727] Gen Physiol Biophys 28 Spec No Focus(-): F55-64 (2009)
2011  
252
Meta-analysis: the diagnostic yield of chromoendoscopy for detecting dysplasia in patients with colonic inflammatory bowel disease.
[21128987] Aliment Pharmacol Ther 33(3): 304-12 (2011)
2010  
253
A large-scale meta-analysis to refine colorectal cancer risk estimates associated with MUTYH variants.
[21063410] Br J Cancer 103(12): 1875-84 (2010)
2010  
254
Cell surface markers in colorectal cancer prognosis.
[21339979] Int J Mol Sci 12(1): 78-113 (2010)
PMC   
255
Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC).
[24399885] Cancer Manag Res 5():377-85 (2013)
PMC   
256
Interleukin-17: a promoter in colorectal cancer progression.
[24382972] Clin Dev Immunol 2013():436307 (2013)
PMC   
257
The molecular genetics of colorectal cancer.
[24416503] Frontline Gastroenterol 5(1):26-30 (2014)
PMC   
258
Much of the genetic risk of colorectal cancer is likely to be mediated through susceptibility to adenomas.
[22999960] Gastroenterology 144(1):53-5 (2013)
PMC   
259
Gefitinib, Fluorouracil, Oxaliplatin, and Leucovorin (IFOX) Regimen for Colorectal Cancer.
[24474830] Hosp Pharm 48(11):905-11 (2013)
PMC   
260
Future directions for monitoring treatment response in colorectal cancer.
[24396497] J Cancer 5(1):44-57 (2014)
PMC   
261
Current approaches and challenges for monitoring treatment response in colon and rectal cancer.
[24396496] J Cancer 5(1):31-43 (2014)
PMC   
262
Irinotecan, continuous 5-fluorouracil, and low dose of leucovorin (modified FOLFIRI) as first line of therapy in recurrent or metastatic colorectal cancer.
[16295778] Korean J Intern Med 20(3):205-9 (2005)
PMC   
263
Genomic instability in pre-neoplastic colonic lesions.
[23396367] Oncogene 32(46):5331-2 (2013)
PMC   
264
A study of genomic instability in early preneoplastic colonic lesions.
[23246972] Oncogene 32(46):5333-7 (2013)
PMC   
265
Recurrence of early stage colon cancer predicted by expression pattern of circulating microRNAs.
[24400111] PLoS One 9(1):e84686 (2014)
PMC   
266
Advances in radiotherapy and targeted therapies for rectal cancer.
[24415852] World J Gastroenterol 20(1):1-5 (2014)
PMC   
267
A second family with probable CRAC (colorectal adenomata and carcinoma) syndrome--a new familial cancer.
[10595264] Dis Markers 15(1-3):120-2 (1999)
PMC   
268
Treatment of lateral pelvic nodes metastases from rectal cancer: the future prospective.
[24629807] G Chir 34(9-10):245-8 (2013)
PMC   
269
Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer.
[23408352] Gut 63(2):317-25 (2014)
PMC   
270
A gene expression and pre-mRNA splicing signature that marks the adenoma-adenocarcinoma progression in colorectal cancer.
[24516561] PLoS One 9(2):e87761 (2014)
PMC   
271
Field cancerization in the colon: a role for aberrant DNA methylation?
[24760232] Gastroenterol Rep (Oxf) 2(1):16-20 (2014)
PMC   
272
Re-evaluation of indications and outcomes of endoscopic excision procedures for colorectal tumors: a review.
[24760234] Gastroenterol Rep (Oxf) 2(1):27-36 (2014)
PMC   
273
Overview of single-port laparoscopic surgery for colorectal cancers: past, present, and the future.
[24574772] World J Gastroenterol 20(4):997-1004 (2014)
PMC   
274
Accumulation of aberrant DNA methylation during colorectal cancer development.
[24574770] World J Gastroenterol 20(4):978-87 (2014)
PMC   
275
Cysteinyl leukotrienes and their receptors: bridging inflammation and colorectal cancer.
[24574769] World J Gastroenterol 20(4):968-77 (2014)
PMC   
276
Circulating and stool nucleic acid analysis for colorectal cancer diagnosis.
[24574768] World J Gastroenterol 20(4):957-67 (2014)
PMC   
277
Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer.
[24574767] World J Gastroenterol 20(4):943-56 (2014)
PMC   
278
How to select the optimal treatment for first line metastatic colorectal cancer.
[24574764] World J Gastroenterol 20(4):899-907 (2014)
PMC   
279
Colorectal cancer biomarkers: to be or not to be? Cautionary tales from a road well travelled.
[24574763] World J Gastroenterol 20(4):888-98 (2014)
PMC   
280
Evolving treatment strategies for colorectal cancer: a critical review of current therapeutic options.
[24574762] World J Gastroenterol 20(4):877-87 (2014)
PMC   
281
Colorectal cancer disparities: issues, controversies and solutions.
[24574761] World J Gastroenterol 20(4):869-76 (2014)
PMC   
282
Intra-arterial therapies for metastatic colorectal cancer.
[24436513] Semin Intervent Radiol 30(1):12-20 (2013)
PMC   
283
Serrated pathway in colorectal carcinogenesis.
[24627599] World J Gastroenterol 20(10):2634-40 (2014)
PMC   
284
Interleukin-13 and its receptors in colorectal cancer (Review).
[24649010] Biomed Rep 1(5):687-690 (2013)
PMC   
285
Management of colorectal polyp cancers.
[23131228] Ann R Coll Surg Engl 94(8):574-8 (2012)
PMC   
286
Differential expression of carbohydrate antigen 19-9 in human colorectal cancer: A comparison with colon and rectal cancers.
[24649295] Mol Clin Oncol 1(6):1072-1078 (2013)
PMC   
287
Serrated polyposis: rapid and relentless development of colorectal neoplasia.
[22490521] Gut 62(3):404-8 (2013)
PMC   
288
Biomarkers in precision therapy in colorectal cancer.
[24759962] Gastroenterol Rep (Oxf) 1(3):166-83 (2013)
PMC   
289
Colorectal cancer in patients seen at the teaching hospitals of Guadeloupe and Martinique: discrepancies, similarities in clinicopathological features, and p53 status.
[24679126] BMC Clin Pathol 14(1):12 (2014)
PMC   
290
Colorectal cancer: prevention and management of metastatic disease.
[24783222] Biomed Res Int 2014():782890 (2014)
PMC   
291
Lynch syndrome from a surgeon perspective: retrospective study of clinical impact of mismatch repair protein expression analysis in colorectal cancer patients less than 50 years old.
[24533633] BMC Surg 14():9 (2014)
PMC   
292
The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia.
[22019796] Clin Gastroenterol Hepatol 10(3):272-7.e1 (2012)
PMC   
293
Identification of Genetic Susceptibility Loci for Colorectal Tumors in a Genome-Wide Meta-analysis.
[23266556] Gastroenterology 144(4):799-807.e24 (2013)
PMC   
294
Prognostic value of mandard and dworak tumor regression grading in rectal cancer: study of a single tertiary center.
[24729903] ISRN Surg 2014():310542 (2014)
PMC   
295
Future directions for the early detection of colorectal cancer recurrence.
[24790655] J Cancer 5(4):272-80 (2014)
PMC   
296
Early detection of colorectal cancer recurrence in patients undergoing surgery with curative intent: current status and challenges.
[24790654] J Cancer 5(4):262-71 (2014)
PMC   
297
Should we move beyond VEGF inhibition in metastatic colorectal cancer? Lessons from early phase clinical trials.
[24772337] J Gastrointest Oncol 5(2):99-103 (2014)
PMC   
298
An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer.
[24674871] Oncologist 19(4):350-1 (2014)
PMC   
299
Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer.
[23580238] Oncologist 18(4):377-8 (2013)
PMC   
300
Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies.
[24922745] BMJ 348(): (2014)
PMC   
301
Clinicopathological characteristics of laterally spreading colorectal tumor.
[24751926] PLoS One 9(4):e94552 (2014)
PMC   
302
Interval to surgery after neoadjuvant treatment for colorectal cancer.
[24764663] World J Gastroenterol 20(15):4256-62 (2014)
PMC   
303
Multimodal imaging evaluation in staging of rectal cancer.
[24764662] World J Gastroenterol 20(15):4244-55 (2014)
PMC   
304
Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer.
[24764661] World J Gastroenterol 20(15):4230-43 (2014)
PMC   
305
Microscopic features of colorectal neoplasia in inflammatory bowel diseases.
[24696602] World J Gastroenterol 20(12):3164-72 (2014)
PMC   
306
Colonic and anal metastases from pancreato-biliary malignancies.
[24707155] World J Gastroenterol 20(13):3693-7 (2014)
PMC   
307
Evidence based medicine and surgical approaches for colon cancer: evidences, benefits and limitations of the laparoscopic vs open resection.
[24707154] World J Gastroenterol 20(13):3680-92 (2014)
PMC   
308
Transcription factor ERG is a specific and sensitive diagnostic marker for hepatic angiosarcoma.
[24707153] World J Gastroenterol 20(13):3672-9 (2014)
PMC   
309
Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer.
[24744578] World J Gastroenterol 20(14):3858-74 (2014)
PMC   
310
Current and future molecular diagnostics in colorectal cancer and colorectal adenoma.
[24744577] World J Gastroenterol 20(14):3847-57 (2014)
PMC   
311
Role of preoperative CT colonography in patients with colorectal cancer.
[24744573] World J Gastroenterol 20(14):3795-803 (2014)
PMC   
312
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
[24744571] World J Gastroenterol 20(14):3751-61 (2014)
PMC   
313
Natural history of hepatic metastases from colorectal cancer--pathobiological pathways with clinical significance.
[24744570] World J Gastroenterol 20(14):3719-37 (2014)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.


  • Kolorektales Karzinom


  • Search PubMed and many other databases on the combined search terms

    GG: colon cancer
    GG: rectum cancer
    GG: colorectal cancer

  • Kolon und Rektum (Neubildung)

  • The BDOM Bibliographic Dictionary of Medicine is a curated collection of free medical articles tagged to concepts.
    Contents until 2011 are reviews from PubMed, contents flagged 'PMC' are regular articles from PubMed Central.
    Search BDOM
    Nephrology Collection
    Radiology Locator

    PubMedCentral monthly collection of free medical articles by major subject

    The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia